Table des matières
-
1. Background
-
2. Methods
-
3. Results
-
3.1. The problem of strict and inconsistent reimbursement of exome sequencing by health insurers
-
3.2. The consequences of strict and inconsistent reimbursement of exome sequencing by health insurers
-
3.2.1. Inequality
-
3.2.2. Delays in diagnostic process
-
3.2.3. Regulations out of step with advances in diagnostic possibilities
-
-
3.3. The importance of taking a broader interpretation of therapeutic and social consequences
-
-
4. Discussion
-
5. Conclusion
